Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Skye Bioscience (SKYE)
NASDAQ:SKYE
Holding SKYE?
Track your performance easily
SKYE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.25 - $19.41
Previous CloseN/A
Volume18.00K
Average Volume (3M)182.96K
Market Cap
$81.91M
Enterprise Value$75.48M
Total Cash (Recent Filing)$64.82K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.99
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding30,338,290
10 Day Avg. Volume104,638
30 Day Avg. Volume182,956
Standard Deviation0.47
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda2.31
Forecast
1Y Price Target
$20.33Price Target Upside664.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Skye Bioscience News
PremiumCompany Announcements
Skye Bioscience Reports Progress in Obesity Drug Trials
PremiumCompany Announcements
Skye Bioscience Appoints New Chairman for Strategic GrowthBulls Say, Bears Say
Bulls Say
Competitive AdvantageNimacimab, Skye Bioscience's lead candidate, is the only monoclonal antibody CB1 inhibitor in development, offering less risk of central nervous system exposure and potentially more convenient monthly dosing.
Market PotentialThe U.S. total addressable market in obese, non-diabetic Americans is approximately $850 billion, suggesting that even modest adoption could translate to blockbuster sales for nimacimab.
Safety ProfileNimacimab has shown a favorable safety profile with no neuropsychiatric adverse effects in more Phase 1 patients compared to a competitor's drug.
Bears Say
Clinical Trial ResultsThe 6% placebo-adjusted weight loss at the low 10 mg dose after 16 weeks is disappointing, with limited additional weight loss at higher doses.
Drug Safety ConcernsFirst-generation CB1 inhibitors led to weight loss up to 10% with better gastrointestinal tolerability than GLP drugs, but their activity in the brain led to suicidal ideation, resulting in one product being pulled from the market and discontinuation of late-stage candidates.
Stock PerformanceSKYE shares are off approximately 45%, trading at about 1.2 times cash, which is considered overdone.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SKYE FAQ
What was Skye Bioscience’s price range in the past 12 months?
Skye Bioscience lowest stock price was $2.25 and its highest was $19.41 in the past 12 months.
What is Skye Bioscience’s market cap?
Skye Bioscience’s market cap is $81.91M.
When is Skye Bioscience’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Skye Bioscience’s earnings last quarter?
Skye Bioscience released its earnings results on Aug 09, 2024. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.195 by -$0.005.
Is Skye Bioscience overvalued?
According to Wall Street analysts Skye Bioscience’s price is currently Undervalued.
Does Skye Bioscience pay dividends?
Skye Bioscience does not currently pay dividends.
What is Skye Bioscience’s EPS estimate?
Skye Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Skye Bioscience have?
Skye Bioscience has 30,338,290 shares outstanding.
What happened to Skye Bioscience’s price movement after its last earnings report?
Skye Bioscience reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.195. Following the earnings report the stock price went up 4.963%.
Which hedge fund is a major shareholder of Skye Bioscience?
Currently, no hedge funds are holding shares in SKYE
---
Skye Bioscience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.33 (664.29% Upside)
$20.33 (664.29% Upside)
Blogger Sentiment
Bullish
SKYE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 919.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.91%
12-Months-Change
Fundamentals
Return on Equity
-54.82%
Trailing 12-Months
Asset Growth
422.52%
Trailing 12-Months
Company Description
Skye Bioscience
Emerald Bioscience, Inc. engages on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids. The company was founded on March 16, 2011 and is headquartered in Long Beach, CA.
---
SKYE Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant progress in clinical trials, strong financial standing, and promising preclinical data, despite increased expenses.Read More>---
SKYE Stock 12 Month Forecast
Average Price Target
$20.33
▲(664.29% Upside)
Technical Analysis
Enveric Biosciences
―
Cyclacel Pharmaceuticals
―
Actinium Pharmaceuticals
―
Kura Oncology
―
RegenXBio
―
Roche Holding
―
Best Analysts Covering SKYE
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-45.07%
reiterated a buy rating 2 months ago
Copying Albert Lowe's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -45.07% per trade.
---